- Getinge’s net sales for Q3 2024 reached SEK7.87 billion, missing the estimate of SEK8.09 billion.
- Acute Care Therapies registered net sales of SEK4.02 billion.
- Life Science net sales came in at SEK1.00 billion, below the estimate of SEK1.08 billion.
- Surgical Workflows achieved net sales of SEK2.85 billion.
- There was a slight organic revenue increase of 0.2% during the quarter.
- The adjusted operating profit was SEK821 million, missing the estimate of SEK892.3 million.
- Operating profit was significantly lower at SEK184 million compared to the estimate of SEK495.2 million.
- Getinge reported orders totaling SEK8.49 billion.
- The gross margin stood at 45.2% for the quarter.
- Comments from Getinge’s CEO, Mattias Perjos, explained a slight decrease in organic sales in Acute Care Therapies, citing reduced hardware and consumable sales due to challenging comparative figures from Q3 2023.
- Life Science experienced a 2.4% decline in organic sales, attributed to a shift in outgoing deliveries of capital goods to Q4 2024 and pending order growth in Bio-Processing not yet reflected in current sales.
- Market analysts recommended 6 buys, 7 holds, and 1 sell for Getinge’s stock.
“`
A look at Getinge AB Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Getinge AB, a company specializing in equipment and systems for sterilization and disinfection, has received a promising overall outlook based on the Smartkarma Smart Scores. With a strong momentum score of 5, indicating positive market performance, Getinge AB is showing promising signs of growth and efficiency in the long term. Additionally, the company scores well in the categories of value, resilience, and growth, further solidifying its position in the market.
Getinge AB‘s commitment to delivering high-quality products to a range of industries including pharmaceuticals, hospitals, dental clinics, and laboratories, coupled with its global reach through subsidiaries and distributors worldwide, positions the company favorably for continued success. Investors looking for a company with a solid foundation and positive growth potential may find Getinge AB to be a compelling choice for their long-term investment goals.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
